Market Place
Sourcing Support
Daré Bio Publishes Positive Findings from Sildenafil Cream Study
10 Dec 2024 //
GLOBENEWSWIRE
Daré Bioscience Reports Q3 2024 Financial Results & Company Update
14 Nov 2024 //
GLOBENEWSWIRE
Daré Bioscience Receives Grant for Non-Hormonal Contraceptive
13 Nov 2024 //
GLOBENEWSWIRE
Daré Bioscience to Host Q3 2024 Results & Update Call Nov 14
07 Nov 2024 //
GLOBENEWSWIRE
Daré Bioscience Receives $10M Award from ARPA-H
23 Oct 2024 //
GLOBENEWSWIRE
Daré Bioscience Announces $15 M Common Stock Purchase Agreement
21 Oct 2024 //
GLOBENEWSWIRE
Daré Publishes Positive Safety Data for Sildenafil Cream in Clinical Study
26 Aug 2024 //
GLOBENEWSWIRE
Daré Bioscience Publishes Positive Safety Data On Sildenafil Cream 3.6%
26 Aug 2024 //
GLOBENEWSWIRE
XOMA Royalty Reports Q2 2024 Results And Recent Activities
13 Aug 2024 //
GLOBENEWSWIRE
Daré Bioscience Announces Publication Of Sildenafil Cream Study
13 Aug 2024 //
GLOBENEWSWIRE
Daré Bioscience Reports Q2 2024 Results And Company Update
12 Aug 2024 //
GLOBENEWSWIRE
Daré Bioscience To Host Q2 2024 Results Call On August 12
05 Aug 2024 //
GLOBENEWSWIRE
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
19 Jul 2024 //
GLOBENEWSWIRE
Daré Bioscience Announces Reverse Stock Split
27 Jun 2024 //
GLOBENEWSWIRE
Daré Publishes Phase 2b Results of Sildenafil Cream for Female Sexual Disorder
24 Jun 2024 //
GLOBENEWSWIRE
Daré Bioscience Reports Q1 2024 Results, Company Update
14 May 2024 //
GLOBENEWSWIRE
Daré To Host Q1 2024 Results And Update Call On May 14
07 May 2024 //
GLOBENEWSWIRE
Daré Bioscience Selected For ARPA-H Investor Hub Network
02 May 2024 //
GLOBENEWSWIRE
Daré`s royalty deal; Qlaris Bio raises $24M
30 Apr 2024 //
ENDPTS
Dare Bioscience Reports Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Daré Bioscience to Host Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Daré Bioscience to Present at the ISSWSH Annual Meeting
22 Feb 2024 //
GLOBENEWSWIRE
Daré Announces Positive Meeting with FDA on Development of Sildenafil Cream
31 Jan 2024 //
GLOBENEWSWIRE
Daré Bioscience Announces Executive Team and Board of Directors Changes
26 Jan 2024 //
GLOBENEWSWIRE
Dare Bioscience Announces Grant to Support Biotherapeutic Product Development
17 Jan 2024 //
GLOBENEWSWIRE
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
26 Dec 2023 //
GLOBENEWSWIRE
Daré Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results
20 Dec 2023 //
GLOBENEWSWIRE
Dare Bioscience Announces Funding Award Notice from the NIH
13 Dec 2023 //
GLOBENEWSWIRE
Daré Bioscience Announces FDA Clearance of IND Application for DARE-VVA1
07 Dec 2023 //
FINANCE YAHOO
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene
04 Dec 2023 //
GLOBENEWSWIRE
Daré Bioscience and Premier Research Extend Strategic Partnership
20 Nov 2023 //
GLOBENEWSWIRE
Dare Bioscience to Present at the Sexual Medicine Society of North America
13 Nov 2023 //
GLOBENEWSWIRE
Daré Bioscience Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Daré Bioscience to Participate in Three November Conferences
06 Nov 2023 //
GLOBENEWSWIRE
Daré Bioscience Announces Achievement of Commercial Under License for XACIATO
16 Oct 2023 //
GLOBENEWSWIRE
Dare Bioscience Announces $7.0 Million Registered Direct Offering
30 Aug 2023 //
GLOBENEWSWIRE
Dare Bios Announces Additional Positive Data from Phase 2b Study of Sildenafil
11 Jul 2023 //
GLOBENEWSWIRE
Dare to Present at 9th Annual International Symposium of Drug Delivery Systems
11 Jul 2023 //
GLOBENEWSWIRE
Dare Bioscience Announces Upcoming Webinar to Review Additional Data
06 Jul 2023 //
GLOBENEWSWIRE
Dare Bioscience Announces Publication in Menopause: The Journal of The NAMS Data
21 Jun 2023 //
GLOBENEWSWIRE
Daré Bioscienceto Host 1Q 2023 FYR & Company Update Conference Call & Webcast
04 May 2023 //
GLOBENEWSWIRE
Daré Bioscience begins Phase I trial of primary dysmenorrhea therapy
23 Feb 2023 //
CLINICAL TRIALS ARENA
Daré Bioscience Announces Publication in Menopause
26 Jan 2023 //
GLOBENEWSWIRE
Daré Bioscience Announces New Development Program, DARE-PDM1
12 Dec 2022 //
GLOBENEWSWIRE
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation
15 Nov 2022 //
GLOBENEWSWIRE
Daré Bioscience Announces Positive Results from DARE-VVA1 Ph1/2 Clinical Study
14 Nov 2022 //
GLOBENEWSWIRE
Daré Bioscience Reports 3Q 2022 Financial Results and Provides a Company Update
10 Nov 2022 //
GLOBENEWSWIRE
Daré Bioscience to Host 3Q FYR and Company Update Conference Call and Webcast
03 Nov 2022 //
GLOBENEWSWIRE
Daré Bioscience Announces Subject Screening for Ph2b RESPOND Study of Sildenafil
01 Nov 2022 //
GLOBENEWSWIRE
Daré Bioscience Announces +VE Efficacy Results from the DARE-HRT1 Ph 1 / 2 Study
17 Oct 2022 //
GLOBENEWSWIRE
Daré Bioscience Announces IDE Approval for a Single Arm, Study of Ovaprene®
10 Oct 2022 //
GLOBENEWSWIRE
Daré Bioscience to Participate in Two Upcoming Conferences
15 Sep 2022 //
GLOBENEWSWIRE
Daré Bioscience to Participate in H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Daré Bioscience Announces Interim Analysis of Ph2b RESPOND Study of Sildenafil
29 Aug 2022 //
GLOBENEWSWIRE
Daré Announces Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate
24 Aug 2022 //
GLOBENEWSWIRE
Daré Bioscience Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Daré Bioscience to Host Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
Dare Bioscience to Participate in Maxim Group Women`s Health Panel
07 Jul 2022 //
GLOBENEWSWIRE
Dare Bioscience Announces Closing of Global License Agreement with Organon
30 Jun 2022 //
GLOBENEWSWIRE
